BNGO/ News und Infos Forum: Community User: Ray7

https://www.globenewswire.com/news-release/2022/08/08/2493598/0/en/Global-Optical-Genome-Mapping-Market-2022-2027-Featuring-Key-Players-Bionano-Genomics-Nabsys-France-Genomique-Others.html

https://quantisnow.com/insight/3240044

https://seekingalpha.com/news/3852826-bionano-gets-us-patent-for-analysis-of-nucleic-acid-fragments-for-genetic-abnormalities?utm_source=webull.com&utm_medium=referral

https://ir.bionanogenomics.com/news-releases/news-release-details/first-published-study-ogm-pediatric-aml-shows-ogm-identifies-mrd/

0260U - $1,424.34 (81277 - 88261) 0264U - $1,424.34 (81277 - 88261) 0267U - $6,455.54 (81425 - 0264U) Healthcare Common Procedure Coding System (HCPCS) codes being considered for Medicare payment under the CLFS for the next calendar year (CY). Two prices are near the top of the historical range (0267U $6739 and 0265U $5475.) These are PRAXIS WGS plus optical genome analysis, and PRAXIS WGS alone. After that, 4 prices are between $1000 and $1500 and five prices are between $2200 and $3200. Gapfilling occurs when no comparable, existing test is available. In this case, the MACs develop a local payment amount for the new test code and CMS calculates an NLA after a year of payment at the local MAC rates based on the median of rates for the test code across all MACs. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings https://docs.google.com/spreadsheets/d/1CVqL7h9ESAmZUzNcmfOp_G0m--Snr7CI/edit#gid=1203485486

https://ir.bionanogenomics.com/news-releases/news-release-details/bionano-genomics-announces-participation-2022-american

https://www.mdpi.com/2227-9059/10/5/1102/htm

https://www.tipranks.com/news/article/bionano-the-bull-thesis-remains-intact-says-analyst/

https://seekingalpha.com/article/4507582-bionano-genomics-inc-bngo-ceo-erik-holmlin-on-q1-2022-results-earnings-call-transcript

https://www.bit.bio/news/how-our-culture-enables-new-technologies

📣🔥Q1 2022 Financial Highlights Total revenue for Q1 2022 was $5.7 million, up 80% from Q1 2021. Gross margin for Q1 2022 was 15%, compared to 33% from Q1 2021. The decrease was primarily due to low yields on our chip consumables produced at one of our contract manufacturers. Gross margin improved over the fourth quarter of 2021 of 4%, primarily due to lower write-off of inventory. Q1 2022 GAAP operating expense was $30.8 million, compared to $12.2 million in Q1 2021. Q1 2022 non-GAAP1 operating expense was $24.3 million, compared to $11.8 million in Q1 2021. Q1 2022 non-GAAP operating expense excludes $5.1 million in stock-based compensation, and $1.4 million in amortization of intangibles. The year-over-year increase was primarily due to increased headcount-related spending, increased R&D expense, and increased marketing expenses. At March 31, 2022, the Company had cash, cash equivalents, and available-for-sale securities of $216.5 million. Chris Stewart, chief financial officer of Bionano added, “Q1 2022 was an excellent quarter for Bionano. We demonstrated strong performance in the face of macro headwinds, with year-over-year revenue growth of 80% and steady increases in our installed base and flowcells sold. We continue to be well-capitalized and remain on track to achieve our revenue guidance in the range of $24 million to $27 million for the year.”

-->https://www.youtube.com/watch?v=DneX4IsXuxU

Conference Call -->